Armistice Capital’s Bluejay Diagnostics BJDX Stock Holding History

Armistice Capital’s Portfolio BJDX Stock Details BJDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$157K	Buy	+131,000	New	+$339K	﹤0.01%	312
2026 Q1	–	Sell	-16,250	Closed	-$43.4K	–	284
2025 Q4	$43.4K	Buy	+16,250	New	+$107K	﹤0.01%	355
2024 Q2	–	Sell	-110	Closed	-$141K	–	274
2024 Q1	$141K	Buy	110 +95	+633%	+$131K	﹤0.01%	300
2023 Q4	$29.6K	Buy	+15	New	+$81.3K	﹤0.01%	266

Other funds holding BJDX

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

LGM

L1 Global Manager Melbourne $142M AUM

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Armistice Capital's BJDX Position: Q2 2026 in Review

Armistice Capital opened a new position in Bluejay Diagnostics (BJDX) in Q2 2026: 131,000 shares worth $157K. The stake represents ﹤0.01% of the portfolio and ranks #312 among its holdings. This is a return to the name: Armistice Capital previously reported a position in BJDX as recently as Q4 2025.

Armistice Capital first reported a position in BJDX in Q4 2023 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold BJDX as of Q2 2026.

Armistice Capital held 131,000 shares of Bluejay Diagnostics worth $157K as of Q2 2026.
Bluejay Diagnostics was a new Armistice Capital position in Q2 2026.
Bluejay Diagnostics made up ﹤0.01% of Armistice Capital's portfolio in Q2 2026, its #312 holding.
Armistice Capital first reported a position in Bluejay Diagnostics in Q4 2023 and has held it in 4 quarters since.
8 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.